SRPT

Sarepta Therapeutics develops RNA-targeted therapeutics for rare diseases, with their core focus on Duchenne muscular dystrophy (DMD) treatments including approved drugs Exondys 51, Vyondys 53, and Amondys 45 that use antisense oligonucleotide technology to restore dystrophin protein production. The company's gene therapy candidate SRP-9001 for DMD represents a potential blockbuster opportunity, with pivotal trial data expected in 2024 that could unlock a multi-billion dollar addressable market. Beyond DMD, Sarepta is expanding into limb-girdle muscular dystrophies and other rare neuromuscular conditions, leveraging their RNA platform across multiple high-value orphan indications. With current DMD franchise revenues approaching $800 million annually and a robust pipeline addressing unmet medical needs in rare diseases, the company offers compelling risk-adjusted returns despite inherent clinical and regulatory execution risks.